withrituximab-highdosemethotrexate/cytarabine(R-MA)andwith-tlecelllymphoma[J].Haematol,2010,150(2):200-208.
[15]KahlBS,SpurgeonSE,FurmanRR,etal.Aphase1studyofthe
PI3Kdinhibitoridelalisibinpatientswithrelapsed/refractoryman-[16]KyriakosP,PapadopoulosCE,Ruiz-SotoR,etal.KPPapadopou-
sandpharmacodynamicsofSAR245409(voxtalisib,XL765),ano-losCE,Ruiz-SotoR,etal.Efficacy,safety,pharmacokinetictlecelllymphoma(MCL)[J].Blood,2014,123(22):3398-3405.
outstemcelltransplantationinpatientswithuntreatedaggressiveman-[3]BernsteinSH,EpnerE,UngerJM,etal.AphaseⅡmulticenter
trialofhyperCVADMTX/Ara-Candrituximabinpatientswithpre-Oncol,2013,24(6):1587-1593.
viouslyuntreatedmantlecelllymphoma;SWOG0213[J].Ann
[4]GeislerCH,KolstadA,LaurellA,etal.Long-termprogression-
rallyadministeredphosphoinositide3-kinase/mammaliantargetofrapamycininhibitor:aphase1expansioncohortinpatientswithre-
freemunochemotherapysurvivalofmantlewithcellinvivolymphoma-purgedafterstemintensivecellrescuefront:a-linenonranim-domized-
[J].Bloodphase,2008,112(7)2multicenter:2687-study2693.
bytheNordicLymphomaGroup[5]GeislerCH,KolstadA,LaurellA,etal.NordicMCL2trialup-
treateddate:sixyearmantlefollowcelllymphoma-upafterintensivefollowedimmunochemotherapybyforun-
tologous[6]doDelarueoccur[stemRJ,]Haioun.-cellHaematolsupportC,Ribrag,:2012,158(3)stillverylongV,etal.:355-survivalBEAMorCHOP362.
butBEAClaterelapses+au-andDHAPplusrit-
uximabfollowedbyautologousstemcelltransplantationinmantlephomescelllymphomadel′Adulte:aphaseM[,J]Hoster.2BloodstudyE,from,2013,121(1)theGroupeetal.Immunochemotherapy:48-d′Etude53.
desLym-[7]LenzG,Dreylingwith
rituximabprednisoneandcyclophosphamide,doxorubicin,vincristinefailuretreated,butsignificantlynotlong-termimprovesoutcomeresponseandtimetotreatment,andtrialmantlecelllymphoma:resultsinpatientsofaprospectivewithpreviouslyrandomizedun-[J].ofClintheOncolGerman,2005,23(9)LowGrade:1984-Lymphoma1992.
StudyGroup(GLSG)[8]Kluin-NelemansHC,HosterE,HermineO,etal.Treatmentof
2012,367(6)olderpatients:520-with531.
mantle-celllymphoma[J].NEnglJMed,
[9]RummelMJ,NiederleN,MaschmeyerG,etal.Bendamustine
Plusforbel,patientsrituximabmulticentrewithversusindolentCHOPandplus,mantlerituximabasfirst-linetreatmentphase-cell3nonlymphomas-inferiority:antrialopenla[J].-[10]LancetGoyA,,2013,381(9873),randomisedBernsteinSH,Kahl:1203-BS,1210.
etal.Bortezomibinpatientswith
analysesrelapsedofortherefractorymulticentermantlephasecelllymphoma2PINNACLE:updatedstudytime[J]-toevent
Oncol,2009,20(3):520-525.
.Ann[11]BelchA,KouroukisCT,CrumpM,etal.AphaseⅡstudyof
bortezomibofCanadaClinicalinmantlecelllymphoma:theNationalCancerInstitute2007,18(1):116-121.
TrialsGrouptrialIND.150[J].AnnOncol,[12]LammW,KaufmannH,RadererM,etal.Bortezomibcombined
withwithrituximabanddexamethasonechemotherapyrefractoryisanactivemantleregimencellforpatients[J].relapsedHaematologicaand,2011,96(7):1008-1014.
lymphoma[13]HessG,HerbrechtR,RomagueraJ,etal.PhaseⅢstudytoeval-
uatethetreatmenttemsirolimuscomparedwithinvestigator′schoicetherapyforClinWitzigOncolTE,,Reeder2009,27(23)ofrelapsedorCB,LaPlant:3822-refractoryBR3829.
mantlecelllymphoma[J].
[14],etal.AphaseⅡtrialofthe
oral[J].mTORLeukemiainhibitor,2011,25(2)everolimus:341-in347.
relapsedaggressivelymphomalapsed(6):1763-orrefractory1770.
lymphoma[J].LeukLymphoma,2015,56[17]WangML,RuleS,MartinP,etal.TargetingBTKwithIbrutinib
inMedRelapsed,2013,369(6)orRefractory:507-516.
Mantle-CellLymphoma[J].NEnglJ[18]RuleS,ShahN,SallesG,etal.AphaseⅠstudyoftheoralBtk
phomainhibitor[J]ONO.Blood-4059,2013,122(21)inpatientswith:439.relapsed/refractoryB-celllym-
[19]WiernikP,LossosI,TuscanoJ,etal.Lenalidomidemonotherapy
inClinrelapsedOncol,or2008,26(30)refractoryaggressive:4952-4957.
non-Hodgkin′slymphoma[J].[20]GoyA,SinhaR,WilliamsME,etal.Single-agentlenalidomidein
patientsorwithmantle-celllymphomawho[21]studywererefractorytobortezomib:phaserelapsedⅡMCL-or001progressed(EMERGEafter)ZajaF[,J]De.ClinLucaOncolS,Vitolo,2013,31(29)U,etal.:3688-Salvage3695.treatmentwithlena-
lidomidephoma:clinicalanddexamethasoneresultsandeffectsinrelapsedonmicroenvironment/refractorymantleandcellneoanlym--[22]WanggiogenicM,biomarkersFayadL,Wagner[J].Haematologica-BartakN,et,al2012,97(3).Lenalidomide:416-in422.
com-
binationtle-celllymphomawithrituximab:aphaseforpatients1/2clinicalwithrelapsedtrial[J]or.refractoryLancetOncolman,-2012,13(7):716-723.
[23]MorrisonVA,JungSH,JohnsonJ,etal.Therapywithbortezomib
nalplusresultslenalidomideofaphaseforrelapsedⅡtrial/(refractoryCALGB50501mantle)cell[J]lymphoma.LeukLym:fi--
[24]phomaMorschhauser,2015,56(4)FA,Cartron:958-964.
G,ThieblemontC,etal.Obinutuzum-
abCell(GAGAUGUINlymphoma101)monotherapystudyor[mantleJ].J-Clincellinlymphomarelapsed/Oncol,2013,31(23):refractoryresultsfromdiffuse:2912-thephaselargeB-2919.Ⅱ[25]FurtadoM,DyerM,JohnsonR,etal.Ofatumumabmonotherapy
BrinrelapsedJHaematol/refractory,2014,165(4)mantlecell:573-lymphom581.
-aphaseⅡtrial[J].[26]Palanca-WesselsMC,FlinnIW,SehnLH,etal.AphaseIstudy
targetingoftheantiCD-CD7979bbinantibodyrelapsed-drugconjugate(ADC)DCDS4501A
lymphoma(NHL)[J].Blood,or2012,120(refractorySupplB-cell1)non:56.-Hodgkin′s[27]OguraM,AndoK,SuzukiT,etal.AmulticentrephaseⅡstudy
ofcellvorinostatnon‐Hodgkininpatientslymphomawithrelapsedandmantleorrefractorycelllymphomaindolent[J].BBr‐[28]HaematolKaplanLD,,2014,165(6)DeitcherSR,:768-Silverman776.
JJA,etal.PhaseⅡstudyof
vincristinepatientssulfateliposomeinjection(Marqibo)andormantlewithcellrelapsedLymphomaandinrefractoryNeedofdiffusePalliativelargeB-CellrituximablymphomaforLymphoma,2014,14(1):37-42.
(收稿日期Therapy:2015-[J]04-.Leuk
09)
97
百度搜索“77cn”或“免费范文网”即可找到本站免费阅读全部范文。收藏本站方便下次阅读,免费范文网,提供经典小说教育文库套细胞淋巴瘤药物治疗的研究进展(3)在线全文阅读。
相关推荐: